These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37564202)

  • 21. microRNA-206 overexpression inhibits epithelial-mesenchymal transition and glomerulosclerosis in rats with chronic kidney disease by inhibiting JAK/STAT signaling pathway.
    Zhao SQ; Shen ZC; Gao BF; Han P
    J Cell Biochem; 2019 Sep; 120(9):14604-14617. PubMed ID: 31148248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.
    Curl CL; Danes VR; Bell JR; Raaijmakers AJA; Ip WTK; Chandramouli C; Harding TW; Porrello ER; Erickson JR; Charchar FJ; Kompa AR; Edgley AJ; Crossman DJ; Soeller C; Mellor KM; Kalman JM; Harrap SB; Delbridge LMD
    J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29858360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction.
    Primessnig U; Schönleitner P; Höll A; Pfeiffer S; Bracic T; Rau T; Kapl M; Stojakovic T; Glasnov T; Leineweber K; Wakula P; Antoons G; Pieske B; Heinzel FR
    Eur J Heart Fail; 2016 Aug; 18(8):987-97. PubMed ID: 27135883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.
    Streng KW; Nauta JF; Hillege HL; Anker SD; Cleland JG; Dickstein K; Filippatos G; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Zannad F; Damman K; van der Meer P; Voors AA
    Int J Cardiol; 2018 Nov; 271():132-139. PubMed ID: 30482453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anemia has an impact on prognosis in heart failure with preserved ejection fraction with mild chronic kidney disease.
    Okuno K; Naito Y; Asakura M; Sugahara M; Horimatsu T; Yasumura S; Tahara S; Nagai T; Saito Y; Yoshikawa T; Masuyama T; Ishihara M; Anzai T
    Int J Cardiol Heart Vasc; 2021 Jun; 34():100796. PubMed ID: 34095449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
    Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
    Alex L; Russo I; Holoborodko V; Frangogiannis NG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.
    Toledo C; Andrade DC; Lucero C; Arce-Alvarez A; Díaz HS; Aliaga V; Schultz HD; Marcus NJ; Manríquez M; Faúndez M; Del Rio R
    J Physiol; 2017 Apr; 595(8):2479-2495. PubMed ID: 28181258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction.
    Tanaka K; Wilson RM; Essick EE; Duffen JL; Scherer PE; Ouchi N; Sam F
    Circ Heart Fail; 2014 Nov; 7(6):976-85. PubMed ID: 25149095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of Na
    Primessnig U; Bracic T; Levijoki J; Otsomaa L; Pollesello P; Falcke M; Pieske B; Heinzel FR
    Eur J Heart Fail; 2019 Dec; 21(12):1543-1552. PubMed ID: 31762174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Triiodothyronine Treatment in an Animal Model of Heart Failure with Preserved Ejection Fraction.
    Neves JS; Leite AR; Conceição G; Gonçalves A; Borges-Canha M; Vale C; Von-Hafe M; Martins D; Miranda-Silva D; Leite S; Rocha-Oliveira E; Sousa-Mendes C; Chaves J; Lourenço IM; Grijota-Martínez C; Bárez-López S; Miranda IM; Almeida-Coelho J; Vasques-Nóvoa F; Carvalho D; Lourenço A; Falcão-Pires I; Leite-Moreira A
    Thyroid; 2023 Aug; 33(8):983-996. PubMed ID: 37140469
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function.
    Mavrakanas TA; Khattak A; Wang W; Singh K; Charytan DM
    Kidney Blood Press Res; 2019; 44(5):1247-1258. PubMed ID: 31476759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular ejection fraction.
    Rouhana S; Farah C; Roy J; Finan A; Rodrigues de Araujo G; Bideaux P; Scheuermann V; Saliba Y; Reboul C; Cazorla O; Aimond F; Richard S; Thireau J; Fares N
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):230-242. PubMed ID: 30463691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-omics approach for identification of molecular alterations of QiShenYiQi dripping pills in heart failure with preserved ejection fraction.
    Huang Y; Zhang K; Wang X; Guo K; Li X; Chen F; Du R; Li S; Li L; Yang Z; Zhuo D; Wang B; Wang W; Hu Y; Jiang M; Fan G
    J Ethnopharmacol; 2023 Oct; 315():116673. PubMed ID: 37268257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder.
    Patel RN; Sharma A; Prasad A; Bansal S
    Kidney Med; 2023 Dec; 5(12):100705. PubMed ID: 38046909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction.
    Takei M; Kohsaka S; Shiraishi Y; Goda A; Izumi Y; Yagawa M; Mizuno A; Sawano M; Inohara T; Kohno T; Fukuda K; Yoshikawa T;
    Circ Heart Fail; 2015 May; 8(3):527-32. PubMed ID: 25737498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients.
    Mark PB; Mangion K; Rankin AJ; Rutherford E; Lang NN; Petrie MC; Stoumpos S; Patel RK
    Clin Kidney J; 2022 Dec; 15(12):2186-2199. PubMed ID: 36381379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics.
    Ben-Nun D; Buja LM; Fuentes F
    Cardiovasc Pathol; 2020; 49():107243. PubMed ID: 32629211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
    Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
    Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.
    van der Pol A; Gil A; Tromp J; Silljé HHW; van Veldhuisen DJ; Voors AA; Hoendermis ES; Grote Beverborg N; Schouten EM; de Boer RA; Bischoff R; van der Meer P
    Cardiovasc Res; 2018 Dec; 114(14):1871-1882. PubMed ID: 30032247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.